| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2005;46:349.)
© 2005 American Heart Association, Inc.
Original Articles |
From the Department of Internal Medicine (T.M., H.K., K.I., T.O., K.S., N.O., T. Saruta), Keio University School of Medicine, Tokyo, Japan; Department of Physiology (H.O., A.K.), Showa University School of Medicine, Tokyo, Japan; and Discovery Laboratory (T. Sugaya), Tanabe Seiyaku Co, Ltd, Osaka, Japan.
Correspondence to Hiroo Kumagai, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. E-mail hkumagai{at}sc.itc.keio.ac.jp
| Abstract |
|---|
|
|
|---|
Key Words: angiotensin antagonist angiotensin II brain central nervous system mice receptors, angiotensin II sympathetic nervous system
| Introduction |
|---|
|
|
|---|
Ang II has 2 major receptor subtypes: the AT1 and AT2 receptors.8 A single gene on chromosome 3 encodes the AT1 receptor in humans,9 whereas 2 AT1 receptor subtypes, AT1a and AT1b, encoded by distinct genes on different chromosomes, have been identified in rodents.10 AT1a receptors are predominant in most tissues (vascular smooth muscle, liver, lung, and kidney), whereas AT1b receptor expression is restricted to the adrenal gland and anterior pituitary.10,11 AT2 receptors are known to be expressed in high levels in several tissues of developing and young animals and then to decrease in density with age.12 Many studies in animals have provided new insights into the roles of AT1 and AT2 receptors using gene transfer or transgenic techniques or antisense gene transfer technology.1318
There are no receptor binding or immunostaining data that indicate that the RVLM contains AT1b and AT2 receptors, either in adult or neonatal mice. Nonetheless, we performed intracellular recordings (whole-cell patch-clamp technique) of RVLM neurons in neonatal AT1a receptor knockout (AT1a KO) mice and wild-type (WT; C57BL/6J) mice during superfusion with Ang II and its AT1 and AT2 receptor blockers to clarify the role of each receptor in the RVLM electrophysiologically. Our data provide physiological evidence for the existence of AT1b and AT2 receptors in the RVLM of neonatal mice.
| Methods |
|---|
|
|
|---|
|
Using the whole-cell patch-clamp technique, we observed intracellular recordings of RVLM bulbospinal neurons, which met the following criteria. (1) The RVLM neurons with discharges that were synchronized with phrenic activity were assumed to be respiratory neurons20 and were excluded from this study. Figure 1B shows representative data of simultaneous recordings of RVLM neuron and phrenic nerve activity. (2) The electrode tip was filled with a solution containing 1% Lucifer-yellow (Aldrich Chemical), which spontaneously diffused into the neurons during the intracellular recordings to verify the location of the neurons examined.21 (3) To determine whether the RVLM neuron recorded is a bulbospinal neuron, we routinely stimulated (5 to 30 V; 0.1 ms; single pulse) the ipsilateral Th2 spinal segment with a tungsten electrode and selected only the RVLM neuron that exhibited an antidromic action potential (Figure 1C).7,19
The RVLM neurons of both strains of mice were classified into 3 types: regularly firing neurons, irregularly firing neurons (Figure 2), and silent-type neurons (data not shown). Regularly firing and irregularly firing neurons showed spontaneous firing. Silent type neurons did not show spontaneous firing, and they were activated only during current-induced depolarization. Irregularly firing neurons exhibited many excitatory postsynaptic potentials, whereas regularly firing neurons rarely showed excitatory postsynaptic potentials.
|
The electrode solution consisted of (in mmol/L) 130 potassium gluconate, 10 HEPES, 10 EGTA, 1 CaCl2, and 1 MgCl2, adjusted to a pH of 7.2 to 7.4 with potassium hydroxide.
Drugs and Protocols
All drugs were dissolved in standard aCSF. Drugs and solutions were applied at a speed of 2 to 3 mL/min to the preparation. To examine the effects of Ang II on RVLM bulbospinal neurons, we performed superfusion with Ang II. We selected 3 and 6 µmol/L of Ang II, the same concentrations that we had used previously in rats.7 To examine the AT1 receptor-mediated effects of Ang II, we performed superfusions with the AT1 receptor blocker candesartan. Candesartan (Takeda Chemical Industries) was dissolved in 1 mol/L NaOH solution, and the pH was adjusted to 7.3 by the addition of HCl. We used 0.06 and 0.12 µmol/L of candesartan, the same concentration as used previously in rats.7 We applied 6 µmol/L of Ang II for 20 minutes, immediately after the end of 20-minute superfusion with 0.12 µmol/L of candesartan. To assess the AT2 receptor-mediated effects of Ang II, we performed superfusions with the AT2 receptor blocker PD123319 (Sigma). Because the effect of 100 nmol/L Ang II on neurons was prevented by 1 µmol/L PD123319,22 we used 60 and 120 µmol/L of PD123319, doses presumably capable of antagonizing the effect of 6 µmol/L of Ang II. We applied 6 µmol/L of Ang II plus PD123319 (60 and 120 µmol/L) for 20 minutes, immediately after the end of 20-minute superfusion with the same concentration of PD123319.
Statistics
Statistical analyses were performed using SPSS 11.5. Baseline values between AT1a KO mice and WT mice and between regularly and irregularly firing neurons were compared with an unpaired t test (2-tailed). Membrane potentials before and after superfusion with drugs were compared with a paired t test (2-tailed). All data were expressed as mean±SEM. P <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
Effects of Ang II on RVLM Bulbospinal Neurons
One to 2 minutes after the start of superfusion with 6 µmol/L Ang II, RVLM bulbospinal neurons of WT mice depolarized, and the firing rate increased (Figure 3A, right panel). This response was similar when comparing regularly and irregularly firing neurons. After that, a tendency to repolarize was observed for 2 to 3 minutes, although the membrane potential remained less negative than that at the presuperfusion level. This represents the accommodation of the neurons to the Ang II stimulus. Thus, the neuronal response of Ang II was biphasic. We quantified the membrane depolarization of the first phase. The neurons for WT mice depolarized with 3 µmol/L Ang II (2.5±0.6 mV; n=6) and with 6 µmol/L Ang II (4.6±1.0 mV; n=12).
|
In contrast, 1 to 2 minutes after the start of superfusion with 6 µmol/L Ang II, RVLM bulbospinal neurons of AT1a KO mice hyperpolarized, and the firing rate decreased (Figure 3A, left panel). This time course was almost the same in regularly and irregularly firing neurons. This response to Ang II was also biphasic. The membrane potential depolarized within 2 to 3 minutes after the hyperpolarization, but it remained below the presuperfusion level. We quantified the membrane hyperpolarization during the first phase. The neurons for AT1a KO mice hyperpolarized with 6 µmol/L Ang II (2.3±0.5 mV; n=10). In this case, 8 of 10 neurons hyperpolarized, and in 2 neurons, there was no response. We also examined the effect of 3 µmol/L Ang II on the RVLM neurons of AT1a KO mice, but it elicited no changes (0.0±0.5 mV; n=6). The difference between the change in membrane potential elicited by Ang II (6 µmol/L) in WT mice and AT1a KO mice was statistically significant. Figure 3B clearly shows that superfusion with Ang II (6 µmol/L) hyperpolarized RVLM bulbospinal neurons of AT1a KO mice, whereas it depolarized those of WT mice.
Effects of Candesartan on RVLM Neurons
Candesartan (0.06 and 0.12 µmol/L) did not significantly change the membrane potential of either WT mice or AT1a KO mice. However, pretreatment with 0.12 µmol/L of candesartan prevented the Ang II (6 µmol/L)induced depolarization in the RVLM of WT mice (from 4.6±1.0 mV [n=12] to 0.5±0.4 mV [n=6]). This effect was similar between regularly and irregularly firing neurons. In contrast, pretreatment with 0.12 µmol/L of candesartan did not significantly affect the Ang II (6 µmol/L)induced hyperpolarization in the RVLM of AT1a KO mice.
Effects of PD123319 on RVLM Neurons in AT1a KO Mice
PD123319 depolarized the RVLM bulbospinal neurons of AT1a KO mice and increased the firing rate (Figure 4A). This effect was similar in regularly and irregularly firing neurons. The average depolarization of RVLM bulbospinal neurons in AT1a KO mice was 1.3±0.5 mV (n=9; 60 µmol/L of PD123319) and 2.2±0.6 mV (n=6; 120 µmol/L of PD123319), significant values (before versus after superfusion with PD123319). The effect of PD123319 persisted for >40 minutes after its washout.
|
Effect of PD123319 on Ang II-Induced Hyperpolarization in AT1a KO Mice
Pretreatment with either 60 or 120 µmol/L of PD123319 completely prevented the Ang II (6 µmol/L)induced hyperpolarization of AT1a KO mice. During superfusion with PD123319, Ang II depolarized the RVLM bulbospinal neurons of AT1a KO mice (Figure 4B). This effect was similar in regularly and irregularly firing neurons. In this case, the average depolarization induced by Ang II (6 µmol/L) was 1.8±0.6 mV (n=9; 60 µmol/L of PD123319) and 3.8±1.3 mV (n=5; 120 µmol/L of PD123319), significant values (before versus after superfusion with Ang II).
| Discussion |
|---|
|
|
|---|
After superfusion with 6 µmol/L Ang II, RVLM bulbospinal neurons of WT mice depolarized, and the firing rate increased. This is the same reaction as RVLM neurons of the SHR in our previous study.7 The reason that RVLM neurons of normotensive WT mice were activated by Ang II in a similar fashion to RVLM neurons in the hypertensive rat model SHR is not clear. It may be because of the difference between mice and rats. In any case, the effect of Ang II is one of the important factors for the activation of RVLM neurons in mice and rats.
In contrast, superfusion of RVLM bulbospinal neurons of the AT1a KO mice with 6 µmol/L Ang II produced a hyperpolarization, and the firing rate decreased. Thus, with a lack of AT1a receptors, there was a lack of Ang II-induced depolarization. Therefore, we postulate that AT1a receptors are essential for the depolarization produced by Ang II. Pretreatment with 0.12 µmol/L of candesartan prevented the Ang II (6 µmol/L)induced depolarization in the RVLM of WT mice. This result also supports the importance of AT1 receptors for depolarization induced by Ang II. In another in vivo study, Ito et al14 reported that the pressor responses to intravenously infused Ang II were virtually absent in AT1a KO mice.
Candesartan by itself did not significantly change the membrane potential of either WT mice or AT1a KO mice. In our previous study using rats,7 candesartan induced membrane hyperpolarization and a decrease in the firing rate of RVLM bulbospinal neurons in SHR but not in WKY. The response of RVLM neurons elicited by candesartan in WT mice was similar to that in WKY.
A novel finding of this study is that after superfusion with 6 µmol/L Ang II, RVLM bulbospinal neurons of AT1a KO mice hyperpolarized, and the firing rate decreased. To assess the underlying mechanism of this hyperpolarization, we used the AT2 receptor blocker PD123319. PD123319 depolarized the RVLM bulbospinal neurons of AT1a KO mice and increased the firing rate. These results suggested that, at least in AT1a KO mice, AT2 receptors are crucial for the hyperpolarization produced by Ang II.
Although the role of AT1 receptors in the brain is essential for regulating BP, basal SNA, baroreceptor reflexes, and fluid balance,2326 the role of AT2 receptors is still not fully understood. The AT2 receptors play a role in a modulation of apoptosis, neurite development, and exploratory behavior,17,27,28 and some reports relate AT2 receptors to BP. Ichiki et al16 reported that AT2 KO mice showed a significantly increased BP and increased sensitivity to the pressor action of intravenously infused Ang II. Hein et al17 also reported an increased vasopressor response of AT2 KO mice to intravenous injection of Ang II, but the baseline BP was almost the same between AT2 KO mice and WT mice in their study. A recent study by Li et al29 suggested an antagonistic action of AT2 receptors in the brain against AT1 receptors in the regulation of BP. They reported that the increase in BP elicited by intracerebroventricular injection of Ang II was greater in AT2 KO mice than in WT mice, and the pressor response to a central injection of Ang II in WT mice was exaggerated by PD123319. These results are consistent with our data in that PD123319 depolarized the RVLM bulbospinal neurons of AT1a KO mice and increased the firing rate. We speculate that Ang II hyperpolarizes RVLM neurons through AT2 receptors, and this effect antagonizes that of Ang II through AT1 (especially AT1a) receptors.
The RVLM contains a high density of AT1a receptors,5,6 but the existence of AT2 receptors has not been reported as far as we know. The distribution of brain AT1 receptors is highly conserved across species from rodents to primates and humans, whereas that of AT2 receptors is highly variable.30 In the mouse brain, the presence of mixed populations of AT1 and AT2 receptors is a widespread occurrence.31 For example, the nucleus of the solitary tract expresses only AT1 receptors in rats, whereas mice express AT1 and AT2 receptors in that nucleus.31 We speculate that, at least in neonatal mice, AT2 receptors can exist in the RVLM, but their density is not so high. In mice, Ang II depolarizes RVLM bulbospinal neurons through AT1 (mainly AT1a) receptors and hyperpolarizes those neurons through AT2 receptors. The roles of AT1 and AT2 receptors are naturally antagonistic in the RVLM. Superfusion with Ang II depolarized RVLM bulbospinal neurons of WT mice because the density of AT1 receptors is much higher than that of AT2 receptors. When we applied Ang II to AT1a KO mice, the membrane potential of RVLM bulbospinal neurons was hyperpolarized. We speculate that it is because AT2 receptors became relatively predominant.
During superfusion with PD123319, Ang II depolarized the RVLM bulbospinal neurons of AT1a KO mice. Without the effect of AT1a and AT2 receptors, it is hard to clarify what type of receptor is important for this depolarization. Oliverio et al15 reported AT1b receptors contribute to the regulation of resting BP when AT1a receptors are absent. Therefore, we speculate that depolarization shown in our study may be attributable to AT1b receptors. However, we have not done a histological work in this study, so the existence of AT1a, AT1b, and AT2 receptors should be elucidated in future.
We recognize the limitations of this study. Because the brain stem-spinal cord preparation removes a lot of the inputs from other brain regions, it only retains the network within the medulla oblongata and spinal cord. However, the major reason why we used this preparation here is that we can choose RVLM neurons that monosynaptically project to the spinal cord. In addition, we should explain why we used neonatal mice. This brain stem-spinal cord preparation is well established in the research field of respiratory neurons. Brockhaus et al32 showed that the microenvironment (eg, oxygenation) of neurons in this preparation is satisfactorily maintained in rats until 4 days after birth. Although we cannot extrapolate data obtained in the present study to adult rats, we believe that this study that demonstrated the role of AT2 receptor is important.
Another major question that arises from our study is whether superfusion with aCSF alters the distribution of the AT1/AT2 ratio. We have not measured AT1/AT2 receptor levels in this study. However, we believe that superfusion with aCSF does not change the AT1/AT2 ratio because in our previous study, the depolarization of RVLM bulbospinal neurons induced by Ang II via AT1 receptor was higher in SHR than in WKY.7 This result is consistent with the fact that the expression of AT1 receptor, as determined by immunocytochemical studies, was higher in SHR than in WKY.6 If the ratio of AT1 receptors in SHR/AT1 receptors in WKY was maintained in our previous study, then the AT1/AT2 ratio in RVLM is likely maintained in the current study.
To clarify the mechanisms that underlie the effects of AT2 receptors on AT1-mediated depolarization is also a difficult question. We assume that antagonistic effects of AT2 receptor activation on AT1-mediated depolarization are attributable to opposite effects on potassium channels in the RVLM neurons (ie, the increases and decreases in conductance after AT2 and AT1 receptor activation, respectively). Indeed, Sumners et al33,34 demonstrated that Ang II suppresses neuronal delayed rectifier K+ current (IKv) via AT1 receptors, whereas Ang II stimulates IKv via AT2 receptors. Detailed analyses of the K+ currents in the RVLM neurons remain for future studies.
Perspectives
We demonstrated that superfusion with Ang II depolarized RVLM bulbospinal neurons in WT mice, whereas it hyperpolarized those in AT1a KO mice. AT1 receptors are essential for the Ang II-induced depolarization in WT mice because pretreatment of AT1 receptor blocker candesartan significantly prevented this effect. Because superfusion with the AT2 receptor blocker PD123319 depolarized RVLM neurons in AT1a KO mice, Ang II hyperpolarized RVLM bulbospinal neurons through AT2 receptors.
| Acknowledgments |
|---|
Received February 17, 2005; first decision March 9, 2005; accepted May 28, 2005.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. Gao, W. Wang, W. Wang, H. Li, C. Sumners, and I. H. Zucker Effects of Angiotensin Type 2 Receptor Overexpression in the Rostral Ventrolateral Medulla on Blood Pressure and Urine Excretion in Normal Rats Hypertension, February 1, 2008; 51(2): 521 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Iigaya, H. Kumagai, H. Onimaru, A. Kawai, N. Oshima, T. Onami, C. Takimoto, T. Kamayachi, K. Hayashi, T. Saruta, et al. Novel axonal projection from the caudal end of the ventrolateral medulla to the intermediolateral cell column Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R927 - R936. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |